Intelligence Feed event · Policy · 2026-08-31

    HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC

    Question

    HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC

    Direct answer

    HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-31
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC”, revision 1, evidence through 2026-08-31. https://marketontology.com/market-events/2026-08-31/hutchmed-and-astrazeneca-announce-positive-phase-iii-sanovo-trial-in-nsclc-33f64c

    POLICY
    HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC
    HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.
    HCMAZN
    Impact
    72
    AUG 31
    SIG
    90%
    HCMAZN
    HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC
    HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.
    → Positive Phase III oncology endpoints establish commercial validation for combination therapy approval filings in Chinese and global oncology markets.
    Impact
    HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.
    Affected
    HCMAZN
    Transmission
    Positive Phase III oncology endpoints establish commercial validation for combination therapy approval filings in Chinese and global oncology markets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMpipeline drug commercialization milestones and royalty revenue growthUp1-4wPositive Phase III SANOVO trial results for ORPATHYS plus TAGRISSO in EGFR/MET lung cancer.
    AZNfirst-line lung cancer addressable market expansion for Tagrisso combination therapyUp1-4wAstraZeneca co-develops combination regimen showing significant progression-free survival.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed12.12 2026-08-31-1.73%+14.52%+16.75%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month